label_id large_stringlengths 11 11 | label_name large_stringlengths 36 128 | regulator large_stringclasses 5
values | biomarker_flag large_stringclasses 2
values | testing_level large_stringclasses 5
values | has_prescribing_info large_stringclasses 1
value | has_dosing_info large_stringclasses 1
value | has_alternate_drug large_stringclasses 1
value | has_other_prescribing_guidance large_stringclasses 1
value | cancer_genome large_stringclasses 1
value | prescribing large_stringclasses 1
value | chemicals large_stringlengths 7 91 | genes large_stringclasses 229
values | variants large_stringclasses 77
values | latest_history_date large_stringdate 2013-10-15 00:00:00 2026-08-03 00:00:00 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PA166104775 | Annotation of FDA Label for atorvastatin and LDLR | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | atorvastatin | LDLR | null | 2023-12-04 |
PA166104776 | Annotation of FDA Label for warfarin and CYP2C9, VKORC1 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | null | null | null | Prescribing | warfarin | CYP2C9; VKORC1 | CYP2C9*1; CYP2C9*2; CYP2C9*3; rs9923231 | 2024-11-21 |
PA166104777 | Annotation of FDA Label for clopidogrel and CYP2C19 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | clopidogrel | CYP2C19 | null | 2024-07-17 |
PA166104778 | Annotation of FDA Label for brentuximab vedotin and ALK, BCL2, BCL6, MYC | FDA | On FDA Biomarker List | null | null | null | null | null | Cancer Genome | null | brentuximab vedotin | ALK; BCL2; BCL6; MYC | null | 2026-04-29 |
PA166104779 | Annotation of EMA Label for indacaterol and UGT1A1 | EMA | null | Informative PGx | null | null | null | null | null | null | indacaterol | UGT1A1 | null | 2025-07-16 |
PA166104780 | Annotation of FDA Label for carbamazepine and HLA-B | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | null | Alternate Drug | null | null | Prescribing | carbamazepine | HLA-B | HLA-B*15:02 | 2024-04-26 |
PA166104781 | Annotation of FDA Label for dasatinib and ABL1, BCR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | dasatinib | ABL1; BCR | null | 2024-08-26 |
PA166104782 | Annotation of FDA Label for azathioprine and NUDT15, TPMT | FDA | On FDA Biomarker List | Testing Recommended | Prescribing Info | Dosing Info | Alternate Drug | null | null | Prescribing | azathioprine | NUDT15; TPMT | null | 2023-08-22 |
PA166104783 | Annotation of FDA Label for rasburicase and CYB5R1, CYB5R2, CYB5R3, CYB5R4 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | rasburicase | CYB5R1; CYB5R2; CYB5R3; CYB5R4 | null | 2025-08-25 |
PA166104784 | Annotation of FDA Label for diazepam and CYP2C19, CYP3A4 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | diazepam | CYP2C19; CYP3A4 | null | 2025-01-23 |
PA166104785 | Annotation of FDA Label for erlotinib and EGFR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | erlotinib | EGFR | rs121434568 | 2023-09-01 |
PA166104786 | Annotation of FDA Label for chloroquine and G6PD | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | null | Other Prescribing Guidance | null | Prescribing | chloroquine | G6PD | null | 2023-09-27 |
PA166104787 | Annotation of FDA Label for cevimeline and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | null | Other Prescribing Guidance | null | Prescribing | cevimeline | CYP2D6 | null | 2013-10-25 |
PA166104788 | Annotation of FDA Label for fluoxetine / olanzapine and CYP2D6 | FDA | null | Actionable PGx | Prescribing Info | null | null | Other Prescribing Guidance | null | Prescribing | fluoxetine / olanzapine | CYP2D6 | null | 2025-08-05 |
PA166104789 | Annotation of FDA Label for gefitinib and EGFR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | gefitinib | EGFR | rs121434568 | 2023-09-01 |
PA166104790 | Annotation of FDA Label for imatinib and ABL1, BCR, FIP1L1, KIT, PDGFRA, PDGFRB | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | imatinib | ABL1; BCR; FIP1L1; KIT; PDGFRA; PDGFRB | null | 2025-02-05 |
PA166104791 | Annotation of FDA Label for lapatinib and ERBB2, ESR1, ESR2, PGR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | lapatinib | ERBB2; ESR1; ESR2; PGR | null | 2024-08-26 |
PA166104792 | Annotation of FDA Label for fulvestrant and ERBB2, ESR1, ESR2, PGR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | fulvestrant | ERBB2; ESR1; ESR2; PGR | null | 2024-11-07 |
PA166104793 | Annotation of FDA Label for risperidone and CYP2D6 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | risperidone | CYP2D6 | null | 2025-09-05 |
PA166104794 | Annotation of FDA Label for sodium benzoate / sodium phenylacetate and ARG1, ASL, ASS1, CPS1, NAGS, OTC | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | sodium benzoate / sodium phenylacetate | ARG1; ASL; ASS1; CPS1; NAGS; OTC | null | 2023-09-28 |
PA166104795 | Annotation of FDA Label for busulfan and ABL1, BCR | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | Cancer Genome | null | busulfan | ABL1; BCR | null | 2024-02-03 |
PA166104796 | Annotation of FDA Label for trastuzumab emtansine and ERBB2 | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | trastuzumab emtansine | ERBB2 | null | 2023-09-01 |
PA166104797 | Annotation of FDA Label for letrozole and ESR1, ESR2, PGR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | letrozole | ESR1; ESR2; PGR | null | 2023-09-01 |
PA166104798 | Annotation of FDA Label for propranolol and CYP2D6 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | propranolol | CYP2D6 | null | 2024-11-15 |
PA166104799 | Annotation of FDA Label for tramadol and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | tramadol | CYP2D6 | null | 2017-05-01 |
PA166104800 | Annotation of FDA Label for indacaterol and UGT1A1 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | indacaterol | UGT1A1 | null | 2024-11-08 |
PA166104801 | Annotation of FDA Label for peginterferon alfa-2b and IFNL3 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | peginterferon alfa-2b | IFNL3 | rs12979860 | 2019-04-19 |
PA166104802 | Annotation of FDA Label for capecitabine and DPYD | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | Dosing Info | Alternate Drug | null | null | Prescribing | capecitabine | DPYD | DPYD c.1129-5923C>G, c.1236G>A (HapB3); rs115232898; rs3918290; rs55886062; rs67376798; rs75017182 | 2025-10-08 |
PA166104803 | Annotation of FDA Label for maraviroc and CCR5 | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | maraviroc | CCR5 | null | 2023-08-18 |
PA166104805 | Annotation of FDA Label for thioridazine and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | thioridazine | CYP2D6 | null | 2013-10-25 |
PA166104806 | Annotation of FDA Label for tolterodine and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | tolterodine | CYP2D6 | null | 2013-10-25 |
PA166104807 | Annotation of FDA Label for fluorouracil and DPYD | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | Dosing Info | Alternate Drug | null | null | Prescribing | fluorouracil | DPYD | DPYD c.1129-5923C>G; DPYD c.1679T>G (*13); DPYD c.1905+1G>A (*2A); DPYD c.2846A>T; DPYD c.557A>G | 2026-02-25 |
PA166104808 | Annotation of FDA Label for nelfinavir and CYP2C19, CYP3A4, CYP3A5 | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | nelfinavir | CYP2C19; CYP3A4; CYP3A5 | null | 2024-08-29 |
PA166104809 | Annotation of FDA Label for panitumumab and KRAS, NRAS | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | panitumumab | KRAS; NRAS | null | 2024-08-12 |
PA166104810 | Annotation of FDA Label for mercaptopurine and NUDT15, TPMT | FDA | On FDA Biomarker List | Testing Recommended | Prescribing Info | Dosing Info | null | null | null | Prescribing | mercaptopurine | NUDT15; TPMT | NUDT15*3; TPMT*2; TPMT*3A; TPMT*3C | 2024-06-06 |
PA166104811 | Annotation of FDA Label for quinidine and CYP2D6 | FDA | On FDA Biomarker List | null | null | null | null | null | null | null | quinidine | CYP2D6 | null | 2023-09-07 |
PA166104812 | Annotation of FDA Label for protriptyline and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | protriptyline | CYP2D6 | null | 2013-10-25 |
PA166104813 | Annotation of FDA Label for carvedilol and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | carvedilol | CYP2D6 | null | 2013-10-25 |
PA166104814 | Annotation of FDA Label for drospirenone / ethinyl estradiol and CYP2C19 | FDA | On FDA Biomarker List | null | null | null | null | null | null | null | drospirenone / ethinyl estradiol | CYP2C19 | null | 2025-08-01 |
PA166104815 | Annotation of FDA Label for clozapine and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | null | null | null | Prescribing | clozapine | CYP2D6 | null | 2023-08-23 |
PA166104816 | Annotation of FDA Label for esomeprazole and CYP2C19 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | esomeprazole | CYP2C19 | null | 2024-12-16 |
PA166104817 | Annotation of FDA Label for tretinoin and PML, RARA | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | tretinoin | PML; RARA | null | 2023-09-11 |
PA166104818 | Annotation of FDA Label for voriconazole and CYP2C19 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | voriconazole | CYP2C19 | null | 2025-01-24 |
PA166104819 | Annotation of FDA Label for tamoxifen and ESR1, ESR2, PGR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | tamoxifen | ESR1; ESR2; PGR | null | 2023-09-01 |
PA166104820 | Annotation of FDA Label for doxepin and CYP2C19, CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | doxepin | CYP2C19; CYP2D6 | null | 2013-10-25 |
PA166104821 | Annotation of EMA Label for arsenic trioxide and PML, RARA | EMA | null | Testing Required | null | null | null | null | Cancer Genome | null | arsenic trioxide | PML; RARA | null | 2024-04-15 |
PA166104822 | Annotation of FDA Label for terbinafine and CYP2D6 | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | terbinafine | CYP2D6 | null | 2023-08-24 |
PA166104823 | Annotation of EMA Label for methylene blue and BLVRB, G6PD | EMA | null | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | methylene blue | BLVRB; G6PD | null | 2024-11-12 |
PA166104825 | Annotation of FDA Label for valproic acid and OTC | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | valproic acid | OTC | null | 2023-02-16 |
PA166104826 | Annotation of FDA Label for cetuximab and BRAF, EGFR, KRAS, NRAS | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | cetuximab | BRAF; EGFR; KRAS; NRAS | rs113488022 | 2025-01-16 |
PA166104827 | Annotation of FDA Label for atomoxetine and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | null | null | null | Prescribing | atomoxetine | CYP2D6 | null | 2019-05-09 |
PA166104828 | Annotation of FDA Label for hydralazine / isosorbide dinitrate and NAT2 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | hydralazine / isosorbide dinitrate | NAT2 | null | 2023-09-08 |
PA166104829 | Annotation of FDA Label for tetrabenazine and CYP2D6 | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | Dosing Info | null | null | null | Prescribing | tetrabenazine | CYP2D6 | null | 2013-10-25 |
PA166104830 | Annotation of FDA Label for tiotropium and CYP2D6 | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | tiotropium | CYP2D6 | null | 2023-08-27 |
PA166104831 | Annotation of FDA Label for irinotecan and UGT1A1 | FDA | On FDA Biomarker List | Testing Recommended | Prescribing Info | Dosing Info | null | Other Prescribing Guidance | null | Prescribing | irinotecan | UGT1A1 | UGT1A1*28; UGT1A1*6 | 2024-08-30 |
PA166104832 | Annotation of FDA Label for carisoprodol and CYP2C19 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | null | Other Prescribing Guidance | null | Prescribing | carisoprodol | CYP2C19 | null | 2013-10-25 |
PA166104833 | Annotation of FDA Label for abacavir and HLA-B | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | null | Alternate Drug | null | null | Prescribing | abacavir | HLA-B | HLA-B*57:01 | 2019-05-08 |
PA166104834 | Annotation of FDA Label for lenalidomide | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | lenalidomide | null | null | 2024-05-02 |
PA166104835 | Annotation of FDA Label for fluoxetine and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | null | Other Prescribing Guidance | null | Prescribing | fluoxetine | CYP2D6 | null | 2023-09-07 |
PA166104836 | Annotation of FDA Label for metoprolol and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | metoprolol | CYP2D6 | null | 2023-09-07 |
PA166104837 | Annotation of FDA Label for propafenone and CYP2D6 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | propafenone | CYP2D6 | null | 2025-08-21 |
PA166104838 | Annotation of FDA Label for thioguanine and NUDT15, TPMT | FDA | On FDA Biomarker List | Testing Recommended | Prescribing Info | Dosing Info | null | null | null | Prescribing | thioguanine | NUDT15; TPMT | null | 2013-10-25 |
PA166104839 | Annotation of FDA Label for aripiprazole and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | null | Other Prescribing Guidance | null | Prescribing | aripiprazole | CYP2D6 | null | 2025-03-28 |
PA166104840 | Annotation of EMA Label for lapatinib and ERBB2, ESR1, ESR2 | EMA | null | Testing Required | null | null | null | null | Cancer Genome | null | lapatinib | ERBB2; ESR1; ESR2 | null | 2024-04-21 |
PA166104841 | Annotation of EMA Label for clopidogrel and CYP2C19 | EMA | null | Informative PGx | null | null | null | null | null | null | clopidogrel | CYP2C19 | CYP2C19*2; CYP2C19*3; CYP2C19*4; CYP2C19*5; CYP2C19*6; CYP2C19*7; CYP2C19*8 | 2024-07-17 |
PA166104842 | Annotation of FDA Label for nilotinib and ABL1, BCR | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | nilotinib | ABL1; BCR | null | 2025-01-15 |
PA166104843 | Annotation of FDA Label for celecoxib and CYP2C9 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | Alternate Drug | null | null | Prescribing | celecoxib | CYP2C9 | CYP2C9*3 | 2025-07-03 |
PA166104844 | Annotation of EMA Label for erlotinib and EGFR | EMA | null | Testing Required | null | null | null | null | Cancer Genome | null | erlotinib | EGFR | null | 2024-04-16 |
PA166104845 | Annotation of FDA Label for dapsone and CYB5R3 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | dapsone | CYB5R3 | null | 2024-07-19 |
PA166104846 | Annotation of FDA Label for arsenic trioxide and PML, RARA | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | arsenic trioxide | PML; RARA | null | 2023-09-01 |
PA166104847 | Annotation of FDA Label for venlafaxine and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | venlafaxine | CYP2D6 | null | 2013-10-25 |
PA166104848 | Annotation of FDA Label for rabeprazole and CYP2C19 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | rabeprazole | CYP2C19 | null | 2025-01-24 |
PA166104850 | Annotation of FDA Label for isoniazid / pyrazinamide / rifampin and NAT2 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | isoniazid / pyrazinamide / rifampin | NAT2 | null | 2025-02-05 |
PA166104851 | Annotation of FDA Label for ticagrelor and CYP2C19 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | ticagrelor | CYP2C19 | null | 2017-03-16 |
PA166104852 | Annotation of FDA Label for citalopram and CYP2C19 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | null | null | null | Prescribing | citalopram | CYP2C19 | null | 2020-09-22 |
PA166104853 | Annotation of FDA Label for cisplatin and TPMT | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | cisplatin | TPMT | null | 2024-07-26 |
PA166104854 | Annotation of FDA Label for fluvoxamine and CYP2D6 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | null | Other Prescribing Guidance | null | Prescribing | fluvoxamine | CYP2D6 | null | 2024-07-22 |
PA166104855 | Annotation of FDA Label for boceprevir and IFNL3 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | boceprevir | IFNL3 | rs12979860 | 2024-07-26 |
PA166104856 | Annotation of FDA Label for amitriptyline and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | amitriptyline | CYP2D6 | null | 2024-07-18 |
PA166104857 | Annotation of FDA Label for trimipramine and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | trimipramine | CYP2D6 | null | 2024-07-19 |
PA166104858 | Annotation of FDA Label for vemurafenib and BRAF | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | vemurafenib | BRAF | rs113488022 | 2023-09-01 |
PA166104859 | Annotation of FDA Label for crizotinib and ALK, ROS1 | FDA | On FDA Biomarker List | Testing Required | null | null | null | null | Cancer Genome | null | crizotinib | ALK; ROS1 | null | 2023-09-01 |
PA166104860 | Annotation of FDA Label for phenytoin and CYP2C9, HLA-B | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | Dosing Info | Alternate Drug | null | null | Prescribing | phenytoin | CYP2C9; HLA-B | CYP2C9*2; CYP2C9*3; HLA-B*15:02 | 2024-09-18 |
PA166104862 | Annotation of FDA Label for desipramine and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | desipramine | CYP2D6 | null | 2013-10-25 |
PA166104863 | Annotation of FDA Label for dexlansoprazole and CYP2C19 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | dexlansoprazole | CYP2C19 | null | 2025-01-23 |
PA166104864 | Annotation of FDA Label for paroxetine and CYP2D6 | FDA | On FDA Biomarker List | null | null | null | null | null | null | null | paroxetine | CYP2D6 | null | 2025-08-18 |
PA166104866 | Annotation of FDA Label for pravastatin and APOE | FDA | Formerly on FDA Biomarker List | null | null | null | null | null | null | null | pravastatin | APOE | null | 2023-09-07 |
PA166104867 | Annotation of FDA Label for telaprevir and IFNL3 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | telaprevir | IFNL3 | rs12979860 | 2024-11-18 |
PA166104868 | Annotation of FDA Label for modafinil and CYP2D6 | FDA | On FDA Biomarker List | null | null | null | null | null | null | null | modafinil | CYP2D6 | null | 2024-11-13 |
PA166104869 | Annotation of FDA Label for galantamine and CYP2D6 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | galantamine | CYP2D6 | null | 2023-08-22 |
PA166104870 | Annotation of FDA Label for pimozide and CYP2D6 | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | Dosing Info | null | null | null | Prescribing | pimozide | CYP2D6 | null | 2023-08-28 |
PA166104872 | Annotation of EMA Label for boceprevir and IFNL3 | EMA | null | No Clinical PGx | null | null | null | null | null | null | boceprevir | IFNL3 | null | 2023-08-14 |
PA166104874 | Annotation of FDA Label for sulfamethoxazole / trimethoprim and G6PD, NAT2 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | sulfamethoxazole / trimethoprim | G6PD; NAT2 | null | 2019-10-10 |
PA166104875 | Annotation of FDA Label for clomipramine and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | clomipramine | CYP2D6 | null | 2013-10-25 |
PA166104876 | Annotation of FDA Label for primaquine and G6PD | FDA | On FDA Biomarker List | Testing Required | Prescribing Info | null | Alternate Drug | Other Prescribing Guidance | null | Prescribing | primaquine | G6PD | null | 2017-11-09 |
PA166104877 | Annotation of FDA Label for mycophenolic acid and HPRT1 | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | mycophenolic acid | HPRT1 | null | 2013-10-25 |
PA166104878 | Annotation of FDA Label for methylene blue and G6PD | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | null | null | Prescribing | methylene blue | G6PD | null | 2013-12-17 |
PA166104879 | Annotation of FDA Label for imipramine and CYP2D6 | FDA | On FDA Biomarker List | Informative PGx | null | null | null | null | null | null | imipramine | CYP2D6 | null | 2024-07-23 |
PA166104880 | Annotation of FDA Label for nefazodone and CYP2D6 | FDA | On FDA Biomarker List | No Clinical PGx | null | null | null | null | null | null | nefazodone | CYP2D6 | null | 2023-08-15 |
PA166104881 | Annotation of FDA Label for glyburide and G6PD | FDA | On FDA Biomarker List | Actionable PGx | Prescribing Info | null | Alternate Drug | Other Prescribing Guidance | null | Prescribing | glyburide | G6PD | null | 2024-09-09 |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 46